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Abstract 
Variation in human major histocompatibility genes may influence the risk of squamous cell 
cervical cancer (SCC) by altering the efficiency of the T cell mediated immune response to 
HPV antigens. We used high resolution methods to genotype HLA Class I (A, B, and Cw) and 
Class II (DRB1 and DQB1) loci in 544 women with SCC and 542 controls. Recognizing that 
HLA molecules are co-dominantly expressed, we focused on co-occurring alleles. Among 
137 allele combinations present at >5% in the case or control groups, 36 were significantly 
associated with SCC risk. All but one of the 30 combinations that increased risk included 
DQB1*0301, and 23 included subsets of A*0201-B*4402-Cw*0501-DRB1*0401-DQB1*0301. 
Another combination, B*4402-DRB1*1101-DQB1*0301, conferred a strong risk of SCC (OR 
10.0, 95% CI 3.0-33.3). Among the 6 combinations that conferred a decreased risk of SCC, 4 
included Cw*0701 or DQB1*02. Most multilocus results were similar for SCC that contained 
HPV16; a notable exception was A*0101-B*0801-Cw*0701-DRB1*0301-DQB1*0201 and its 
subsets, which were associated with HPV16+ SCC (OR 0.5, 95% CI 0.3-0.9). The main 
multilocus associations were replicated in studies of cervical adenocarcinoma and vulvar 
cancer. These data confirm that T helper and cytotoxic T cell responses are both important 
cofactors with HPV in cervical cancer etiology, and indicate that co-occurring HLA alleles 
across loci appear to be more important than individual alleles. Thus, certain co-occurring 
alleles may be markers of disease risk that have clinical value as biomarkers for targeted 
screening or development of new therapies. 
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Introduction 
Cervical cancer is the second most common cancer among women worldwide, with nearly 
500,000 new cases and over 270,000 deaths occurring globally each year.(1) It is primarily 
caused by a common sexually transmitted pathogen, oncogenic human papillomavirus 
(HPV). HPV has been shown to meet the causal criteria for cervical cancer, including viral 
presence in tumors, consistent findings of strong associations across a variety of laboratory-
based and epidemiologic studies, a viral dose-response relationship, a pathologic sequence 
in which infection precedes development of lesions, and mechanistic coherence.(2) Since 
HPV is a common infection in young women and cancer is a rare outcome, other factors such 
as individual immune response to the infection are likely necessary to promote persistent 
HPV infection and the development of increasingly severe cervical intraepithelial neoplasia 
that precedes invasive cervical cancer.   
The human leuckocyte antigen (HLA) class I and II molecules play a critical role in the 
manner that HPV peptides are presented to T cells. High-affinity engagement of a T cell 
receptor with an HPV peptide-HLA complex and a costimulatory signal is necessary to 
activate a T cell response, and may vary with HLA type.(3) Class I HLA molecules are found 
on most nucleated cells and present peptides from the cytosol to cytotoxic T cells; on the 
other hand, Class II HLA molecules are found on antigen-presenting cells (e.g., dendritic cells 
and macrophages) and present peptides degraded in intracellular vesicles to helper T 
cells.(4) An effective immune response may require optimal peptide presentation by both 
class I and class II molecules in order to activate efficient helper and effector T cell responses 
to HPV. Subtle changes or impairment in T cell responses may allow escape from immune 
surveillance or induction of immune anergy or tolerance to HPV peptides.  
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In this study we conducted high-resolution HLA typing to assess the risk of squamous 
cell cervical cancer (SCC) associated with class I HLA-A, -B, and -C and class II HLA-DRB1 
and -DQB1 loci. HLA loci are extraordinarily polymorphic, so few haplotypes are present at 
high frequency across all five loci and hence typical haplotype-based association analysis is 
not warranted. Recognizing that HLA molecules are co-dominantly expressed on the cell 
surface (i.e., both alleles at each locus are expressed in heterozygous individuals) and that 
combinations of alleles at various HLA loci are jointly informative, we focused the present 
analysis on co-occurring alleles across HLA loci.  
 
Methods 
 Study Population. Cases were 18-74 year old women diagnosed with invasive 
squamous cell cancer (SCC) while residents of the 3-county metropolitan Seattle area (King, 
Snohomish, and Pierce Counties) in Washington State in two time periods, January 1986 
through June 1998 or January 2000 through December 2004. Cases were ascertained from a 
National Cancer Institute cancer registry based in Seattle (the Cancer Surveillance System, a 
Surveillance and End Results (SEER) registry), and had been assigned International 
Classification of Diseases for Oncology morphology codes 8010-8077 and topography codes 
1800-1809. Controls were identified through random-digit telephone dialing (RDD) among 
female residents of the same counties, and were frequency matched to the age distribution of 
the cases in 5-year groups. Eligible controls for the cervical cancer study had to have an 
intact uterus. Both case and control subjects in this study had to have a residential telephone 
and the ability to communicate in English.  
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In-person interviews covered demographic characteristics as well as reproductive, 
sexual, birth control, hormonal, Pap, and smoking histories. Previous reports from this study 
have examined a variety of risk factors for cervical cancer including HPV status,(5) oral 
contraceptive use, cigarette smoking, and herpes simplex virus,(6) the p53 Arg72Pro 
polymorphism,(7) Chlamydia trachomatis,(8) and HLA class II alleles.(9)  Questions on the 
interview referred to events prior to the diagnosis date (month and year) for cases or an 
assigned date in the past for controls. Control reference dates were matched to the 
distribution of diagnosis dates of the cases.   
The response proportion was 62.6% for cases (744 interviewed out of 1189 cases) 
and 66.5% for controls (1486 interviewed out of 2024 controls). The response proportion for 
controls accounts for the household screening response rate (90.6%, the proportion of all 
potential controls who were screened and found to be eligible), according to our protocol for 
RDD control selection.(10) Collection of samples suitable for DNA extraction started several 
years after interviewing began for the study. Although all case subjects with DNA available 
were included in this study (544 of 744 interviewed cases), controls were sampled to match 
the number of cases in the study. A total of 544 women with SCC and 542 control women 
had samples available for HLA testing at all 5 loci and are included in this analysis.  
 HLA Genotyping.  Peripheral blood samples were collected in Vacutainter tubes 
containing EDTA anticoagulant and processed and stored at -80oC within 24 hours of being 
drawn. DNA was extracted from stored peripheral blood mononuclear cells that had been 
suspended in RPMI 1640/DMSO using a manual phenol:chloroform method, and stored in an 
ultra-low freezer in multiple 0.5 ml aliquot tubes.  Two methods were used to type HLA class I 
and II alleles, both of which used sequence specific oligonucleotide probe (SSOP) reverse 
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format assays (rSSOP). Initially, the Dynal RELI™ system with probe arrays bound to nylon 
membrane strips was employed. Later typing used the One Lambda LabType™ system with 
probe arrays bound to color coded plastic microspheres was used. In both methods, locus-
specific biotinylated primers for HLA DRB1 and DQB1 loci were used to amplify all known 
alleles for exon 2, while locus-specific primers for HLA A, B, and Cw were used to amplify all 
known alleles for exons 2 and 3. Biotinylated amplicons were denatured to single stranded 
DNA and incubated with individual line strips (RELI™) or tubes of pooled microspheres-
probes (LabType™).   Each of the five HLA loci was separately amplified and hybridized with 
locus specific probe arrays. The biotin-labeled amplicons hybridized to those SSOPs that 
contain a target DNA sequence complementary to the sample DNA. After hybridization, a 
stringent wash removed excess, unbound amplicon to ensure specificity.  In the RELI™ 
system, visualization of the amplicon–probe complex consisted of two steps: (a) streptavidin–
horseradish peroxidase (SA-HRP) conjugate bound the biotin–labeled amplicons captured by 
the SSO probes and (b) hydrogen peroxide and tetramethylbenzidine substrate formed a 
blue-colored complex with the SA-HRP conjugate. A transparent overlay with numbered lines 
corresponding to probe locations was placed over each individual membrane strip. Probe 
reactions were scored positive or negative with reference to the positive control.  These 
results were reviewed subject to a second review to ensure accuracy.  In the LabType™ 
system, SSOP reactions were analyzed with Luminex™ Flow Analysis equipment, in which 
the locus specific SSOP-bead arrays are subjected to laser interrogation to identify each 
specific probe and determine the presence (positive hybridization) or absence (negative 
hybridization) of the biotin-labeled amplicon. SSOP reactions for each sample are submitted 
electronically to an HLA analysis program to deduce the HLA type. 
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 The Dynal RELI™ rSSOP method provided sufficient resolution of HLA A, B, C, and 
DQB1 alleles for our analyses. DRB1 alleles were specifically identified by DNA sequencing, 
with separate amplification of the polymorphic DRB1 allele families (DRB1*01, *02, *04, 
*03/11/13/14, *08/12) based on the preliminary rSSOP RELI™ analysis.  DNA sequencing 
used fluorescence-labeled dideoxynucleotide terminator chemistry with analysis on an ABI 
377-XL96 DNA sequencer using ABI Sequence Navigator and HLA Matchmaker software 
(Applied Biosystems).  The One Lambda LabType™ rSSOP method employed a sufficient 
number of probes to assign alleles for our analysis at all HLA loci, although infrequent or rare 
HLA alleles identified by LabType™ were confirmed by DNA sequencing using fluorescence-
labeled dideoxynucleotide terminator chemistry (Atria Genetics) with analysis on an ABI 
3130xl sequencer with Assign™ HLA analysis software (Conexio Genomics). 
For DQB1*02, the difference between DQB1*0201 and *0202 is in exon 3, and the 
typing reagents we use analyze polymorphisms in exon 2. Therefore, specific allele 
assignments were made based on common allele specificities in the presence of DRB1*0301 
or DRB1*0701.(11) Thus, DQB1*02 became DQB1*0201 if a subject carried DRB1*0301 and 
DQB1*0202 if a subject carried DRB1*0701. If a person was typed with DQB1*02 and had 
neither DRB1 *0301 nor *0701, then the DQB1*02 allele could not be inferred, and was kept 
as missing for both allele-level variables.  
HPV Typing of Tumor Tissue. Tissue blocks from 389 of 544 case subjects (71.5%) 
were retrieved from local pathology laboratories, and HPV typing was performed using 
PCR/RFLP (MY09/MY11 L1 consensus and HPV16 and HPV18 E6 type-specific primers, 
with co-amplification of 236 bp or 536 bp fragments of β-globin to test for sample integrity). 
While this would not be the optimal testing method by current standards, our intention was to 
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use the optimal method available at the start of the study and continue with a standard 
approach throughout the study. Newer assays would likely have found additional positive 
samples as well as additional HPV types. Human β-globin DNA was detected in 369 (94.9%) 
of the tumors and HPV DNA was found and typed in 332 of those tumors (90.0%).   
Single Locus Analysis. Alleles present in 5% or more of the case or control subjects 
were included in the main single locus analyses. Odds ratios (ORs) and 95% confidence 
intervals (CIs) for the association between individual alleles within a locus and SCC risk were 
estimated by logistic regression, with adjustment for race (white, non-white). Additional 
analyses were restricted to whites only, but were similar to the race-adjusted analyses and 
are not presented here.   
The Holm procedure was used to assess the likelihood that significant allele estimates 
were due to multiple comparisons.(12) This procedure is similar to the Bonferroni method in 
assessing the potential for type 1 error but with the added benefit of sequentially ordered 
Wald p values to rank the severity of the penalty for multiple comparisons.(13)  Holm p-
values are presented for the statistically significant odds ratios, and were calculated based on 
all tests conducted for each locus in Tables 2 and 3, for all results presented in Table 4, and 
for all results within a cancer site for Table 5. Information on individual alleles found less 
commonly in the study population, (i.e., at <5%), is presented in a supplementary Table 
(Supplementary Table 1) for comparison with other study populations.  
Multilocus Analysis. To focus the analysis with meaningful sample sizes, we 
examined the co-occurring alleles that occurred in more than 5% of the case or control 
population. We used publicly available software (HPlus) to estimate the most commonly co-
occurring alleles (http://qge.fhcrc.org/hplus). Separate categorical variables were constructed 
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to identify those unphased genotypes that include a particular allelic combination versus 
those unphased genotypes that can never give rise to the allelic combination, and we then 
used logistic regression to assess its association with SCC.  Co-occurring alleles identified by 
HPlus that were present in 5% or more of the cases or controls but not significantly 
associated with SCC are presented in a supplement to this report (Supplementary Table 2).  
In a separate analysis of constituent alleles, we compared mutually exclusive 
multilocus combinations of interest to a common reference group in an attempt to determine 
the relative importance of single alleles compared to co-occurring alleles. To limit the number 
of comparisons in these analyses, only the four multilocus combinations of most interest were 
explored.    
Replication of Findings in Other HPV-Related Anogenital Cancers. To assess 
whether the multilocus alleles found to be associated with cervical SCC are 1) not false 
positives, and 2) indicative of an effect of HLA molecules on the pathogenesis of HPV-related 
anogenital cancer more generally, we examined the association of these alleles with cervical 
adenocarcinoma(14) and vulvar carcinoma(15) using cases from our ongoing studies of 
those cancers. In brief, there were HLA results available from 424 squamous cell vulvar 
cancer cases and 501 adenocarcinomas of the cervix, with 66.7% and 68.7% response 
proportions, respectively. A single control group was used for all three case populations, with 
the addition of controls with a prior hysterectomy (n=134) to our vulvar cancer study. 
 
Results 
Consistent with other studies of cervical cancer, women with SCC in this study had 
more sexual partners compared with women without cervical cancer and the cases were 
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more frequently current smokers compared to controls (Table 1). Case and control subjects 
in this study were predominately white by self report, reflecting the racial composition of the 
Seattle area. Among non-whites, more cases than controls identified themselves as Asian or 
Pacific Islanders.  
Race adjusted odds ratios for single locus HLA Class I and II alleles present among at 
least 5% of the case or control subjects are presented in Tables 2 and 3. High-resolution 
DNA-based assay methods resulted in typing 40 A, 74 B, 32 Cw, 45 DRB1, and 17 DQB1 
alleles. We found significantly elevated risks of SCC associated with three class I alleles 
(Table 2) that were present in over 20% of the cases: A*0301 (OR 1.4, 95% CI 1.1-1.9), 
B*4402 (OR 1.9, 95% CI 1.4-2.7), and Cw*0501 (OR 1.6, 95% CI 1.2-2.3). B*1501 was 
associated with a decreased risk of SCC (OR 0.6, 95% CI 0.4-0.9), and was found in 6.3% of 
cases and in 11.3% of the control subjects.  
Two class II alleles (Table 3) were found to confer increased risk associated with SCC, 
i.e., DRB1*1101 (OR 2.1, 95% CI 1.3-3.2) and DQB1*0301 (OR 1.5, 95% 1.1-1.9). 
Decreased risks of SCC were associated with DRB1*1302 (OR 0.5, 95% CI 0.3-0.9) and 
DQB1*02 (OR 0.7, 95% CI 0.6-1.0) which were present among 9.1% and 41.8% of controls, 
respectively.  
In exploratory analyses, co-occurring alleles comprising 2 to 5 loci present in more 
than 5% of the cases or controls were analyzed to comprehensively explore the potential joint 
impact of HLA class I and II genes. There were137 co-occurring allele combinations that 
occurred in >5% of the cases or controls. As shown in Table 4, 36 co-occurring allele 
combinations conferred a significant risk of SCC: 30 were associated with increased risk and 
6 associated with decreased risk.  
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The majority of the extended co-occurring alleles were associated with similar risks as 
lower-order sub-combinations. For example, a 2-fold increased risk of cervical cancer 
associated with the 5-allele combination A*0201-B*4402-Cw*0501-DRB1*0401-DQB1*0301, 
might be explained by the presence of the 4-allele combination B*4402-Cw*0501-
DRB1*0401-DQB1*0301,  the 3-allele combination B*4402-DRB1*0401-DQB1*0301, a 
number of 2 allele combinations, or even by the individual alleles B*4402, DRB1*0401, or 
DQB1-0301. 
The most commonly occurring allele in cases and controls was A*0201; however, this 
gene was not associated with SCC by itself, suggesting that it was passively associated with 
disease risk secondary to significant disequilibrium with alleles that affect risk. Interestingly, 
another common allele, DQB1*0301, was present in all but one of the 30 significant 
increased risks associated with co-occurring alleles (Table 4). The sole exception was 
A*0301-DQB1*0501. However, the risk of SCC associated with the A*0301-DQB1*0501 
combination may have been due to the higher prevalence of DQB1*0301 among cases 
(28.6%) than controls (7.1%) who carried the A*0301-DQB1*0501 alleles (data not shown). 
In Table 4, the most strongly increased risks were associated with B*4402-DRB1*1101 
or B*4402-DRB1*1101-DQB1*0301 (OR 10.5, 95% CI 3.2-34.8 and OR 10.0, 95% CI 3.0-
33.3, respectively). The elevated B*4402-DRB1*1101 estimate is a departure from the 
expected joint effect of these alleles (p for interaction=0.003).  
There were fewer multilocus combinations that conferred a decreased risk of SCC 
than increased risk. Among the co-occurring alleles that conferred decreased risk, over 20% 
of the controls had Cw*0701 or DQB1*02, which were found in four of the six reduced-risk 
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combinations. There were also decreased risks associated with A*0201-B*1501 (OR 0.4, 
95% CI 0.2-0.7) and A*1101-Cw*0401 (OR 0.5, 95% CI 0.3-1.0). 
In the leftmost odds ratio estimates in Table 5, we further explored multilocus 
associations with SCC by using a common reference group for each analysis. Taking this 
approach, the risks for various co-occurring allele combinations were compared to subjects 
without the alleles of interest. For B*4402-DRB1*1101-DQB1*0301 and B*0702-Cw*0702-
DQB1*0301, the elevated risks depend on the multilocus allele combinations, not on 
individual alleles. Similarly, risk-deterring DRB1*0301-DQB1*0201 related estimates (with or 
without B*0801) are lower than estimates for any constituent alleles (i.e., DRB1*0301 or 
DQB1*0201).  
In the Seattle population, B*0702 was in tight linkage with Cw*0702, and the 
combination of these alleles with DQB1*0301 resulted in a strongly elevated risk of SCC (OR 
2.7, 95% CI 1.6-4.6). When we extended this multilocus combination to either include or 
exclude DRB1*1501-DQB1*0602, (which was not by itself associated with SCC risk), both 
strata resulted in similarly increased risks of SCC (B*0702-Cw*0702-DQB1*0301 with 
DRB1*1501-DQB1*0602, OR 2.1, 95% CI 1.0-4.3 and without DRB1*1501-DQB1*0602, OR 
3.3, 95% CI 1.6-6.8), suggesting no effect of DRB1*1501-DQB1*0602 in this population. 
One association of interest in other studies involves DRB1*13-DQB1*06. The 
strongest risk estimates associated with SCC were for the DRB1*13-DQB1*06 allele 
combination (0.6, 95% CI 0.3-1.0). The analysis in Table 5 suggests that neither DRB1*13 or 
DQB1*06 alone is responsible for the decreased risk of SCC, but both are important together. 
Surprisingly, it appears that DRB1*13-DQB1*0301/06 does not confer a decreased risk of 
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SCC (OR 1.1, 95% CI 0.6-1.8), suggesting that the combination of risk conferring (e.g., 
DQB1*0301) and risk decreasing alleles may result in a neutral effect.  
The risk estimates for single alleles associated with SCC were similar when the case 
group was restricted to HPV16 positive cases (HPV16+SCC, n=228) for most of the single 
locus analyses presented in Tables 2 and 3. When the multilocus analyses were restricted to 
tumors that contained HPV16, most risk estimates were similar to those presented in Table 4 
for all SCC and are presented in Supplementary Table 3. Strikingly, the allele combinations 
associated with a decreased risk of HPV16+ are represented by the 5 allele combination 
A*0101-B*0801-Cw*0701-DRB1*0301-DQB1*0201 (OR 0.5, 95% CI 0.3-0.9), and the other 
HPV16-associated risk-decreasing allele combinations are subsets of that combination.  
 Table 5 presents the results of our attempt to replicate allele combination findings for 
cervical SCC using cases of cervical adenocarcinoma (n=537) and squamous cell vulvar 
carcinoma (n=424) from our studies, compared to a shared control group. There was an 
increased risk, but not as strongly increased risk associated with B*4402-DRB1*1101-
DQB1*0301 in the adenocarcinoma of the cervix and vulvar studies. Also, there were 
increased risks associated with B*0702-Cw*0702-DQB1*0301 for all three case groups. 
There was a suggestion that the strong decrease in SCC risk associated with DRB1*0301-
DQB1*0201 seemed to be more important for adenocarcinoma and vulvar cancer when 
B*0801 was also present as part of the allele combination.   
 DRB1*13-DQB1*06 was associated with decreased risk for all three case groups, but 
there was not an increased risk for cancer associated with DRB1*13-DQB1*06 in the 
presence of DQB1*0301. 
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Discussion 
We report associations for extended HLA class I and II multilocus alleles that to our 
knowledge have not been previously reported, such as an increased risk associated with the 
multilocus B*4402-Cw*0501-DRB1*0401-DQB1*0301 (OR 2.3, 95% CI 1.3-3.7) and 
decreased risks associated with allele combinations containing only class I alleles, such as 
A*0201-B*1501 (OR 0.4, 95% CI0.2-0.7) and B*0801-Cw*0701 (OR 0.7, 95% CI 0.5-0.9). In 
this study, B*4402 was found to be a major risk-conferring allele that appears often among 
cases with the known risk allele DQB1*0301. A prior study(16) reported an increased risk of 
progression to neoplasia in 8 out of 88 HPV16 positive women, 6 of whom were B*4402 
carriers. In the current study, carriage of B*4402–DRB1*1101–DQB1*0301 was associated 
with an 11-fold increased risk of SCC (OR 11.5, 95% CI 3.5-38.5 in Table 5). This joint effect 
was reproduced at lower magnitude in two additional case groups of HPV-related anogenital 
cancer: we found a nearly 5-fold increased risk of adenocarcinoma of the cervix (OR 4.9, 
95% CI 1.4-17.2) and vulvar cancer (OR 4.7, 95% CI 2.0-10.7) associated with these co-
occurring alleles. Replication of this association and other multilocus combinations in two 
independent case groups from our anogenital cancer studies suggest that specific co-
occurring HLA alleles may be more important than individual alleles.  
In this population-based study, there were four HLA class I and four class II alleles 
significantly associated with cervical SCC after correction for multiple comparisons. One 
allele from each locus was associated with an elevated risk of SCC: A*0301, B*4402 , 
Cw*0501, DRB1*1101, and DQB1*0301. Three alleles were associated with a decreased risk 
of SCC: B*1501, DRB1*1302, and DQB1*02. As can be seen in Table 4, risk conferring 
alleles tend to occur together. For example, the 5-loci combination A*0201-B*4402-Cw*0501-
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DRB1*0401-DQB1*0301 was associated with a 2-fold elevated risk of SCC, and contained 
three individually significant alleles (B*4402, Cw*0501, and DQB1*0301). 
Previous work from our group(9) and others (17, 18), indicates that risk of cervical 
cancer may depend on specific HLA alleles or HLA-linked genes. As genotyping of the HLA 
region has become more precise, observations of associations between HLA and cervical 
cancer have also become more refined. Consistent findings of increased risk of cervical 
cancer associated with DQB1*0301 and decreased risk associated with DRB1*13 have been 
reported from most populations throughout the world. However, less consistent results for 
other HLA alleles have been reported as well, and may represent population specific or even 
chance findings because of the polymorphic nature of the HLA region genes.     
Several recent studies have examined the risk of cervical neoplasia associated with 
the HLA region. Zoodsma et al.,(19) in a study conducted in the Netherlands, used 
microsatellite markers and two single nucleotide markers (SNPs) on 6p21 and found two 
markers (one near the HLA DQ and DR genes, the other in MICA) that were strongly 
associated with risk of cervical cancer. Engelmark et al. (20) used an affected sib pair 
approach in a Swedish study that performed typing of the five class I and class II loci, and 
reported a strong effect of class II but not class I loci in cervical cancer. A study by 
Hildesheim et al.(21) examined the risk of cervical neoplasia associated with one class I 
allele (B*07), and four class II allele families (DQB1*03, DQB1*06, DRB1*15, and DRB1*13) 
in a nested case-control study in Portland, Oregon. They reported increased risks of cervical 
neoplasia associated with B*07 and DQB1*0302 and decreased risk with DRB1*13.  Wang et 
al., (22) in a study nested within the Guanacaste, Costa Rica, cohort, also reported strong 
risks associated with carriage of these five allele families for cervical neoplasia. A more 
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recent study (23) from this group of investigators found no increased risks for cervical 
neoplasia associated with cervical cancer in a haplotype-based analysis, with high resolution 
typing across A-B-DR alleles in studies conducted in the Eastern US and Costa Rica.    
In a UK study,(24) HLA-B7-positive cervical cancer patients had a significantly poorer 
clinical outcome than HLA-B7-negative patients. A significant component of the effect was 
down-regulation of HLA-B7 expression. In an earlier study, the same group(25) reported that 
an HPV16E6 non-wild type variant was present in 7 of 22 (31.8%) tumors from B7-positive 
cervical cancer patients. They reported that this variant alters the B7 binding epitope in a way 
that may influence cytotoxic T cell recognition. We did not have information on HPV16 viral 
variants in the present study, so a joint effect of B*07 and the HPV16E6 non-wild type variant 
could have been masked. Even without information on viral variants, however, the analysis in 
Table 5 suggests that co-occurrence of B*07 with two other alleles (i.e., B*0702-Cw*0702-
DQB1*0301, OR 2.8, 95% CI 1.7-4.5), is important to increased risk of SCC. 
DRB1*13 carriers may also be at decreased risk for other infectious diseases. HIV 
positive patients with DRB1*13-DQB1*06 had slower progression to AIDS and were better 
suppressors of viral activity than patients with other HLA haplotypes.(26). In another study, 
DRB1*1301 (but not 1302) was associated with decreased risks of malaria and hepatitis 
B.(27) These findings suggest that DRB1*13 may be especially good at presenting viral or 
tumor associated peptides to class II restricted T helper cells and promoting an effective 
immune response. Our study indicates that both DRB1*1301 and DRB1*1302 may be 
important in decreasing cervical cancer risk, but the most strongly decreased risk is 
associated with DRB1*1302. This difference may be due to the one amino acid difference 
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between the two alleles, as DRB1*1302 has a G at the anchor position 86 in the peptide 
binding site compared to a V for DRB1*1301.    
Limitations of this study need to be acknowledged. First, the highly polymorphic nature 
of HLA alleles leads to multiple comparisons and increases the risk of chance associations. 
We used the Holm’s test, a Bonferroni-like method, to estimate the likelihood of a type 1 error 
for the single locus analyses. We also repeated the main exploratory analyses in two other 
case groups from our series of case-control studies of anogenital cancer in the Seattle area: 
women with adenocarcinoma of the cervix and women with vulvar cancer. It will be important 
to repeat these analyses in other populations and with other HPV-related end points to 
understand the reach of these findings; however, replication of the main exploratory findings 
in independent samples in the present study decreases the likelihood of chance findings due 
to multiple comparisons. 
Second, the relatively low proportion of eligible cases (62.6%) and controls (66.5%) 
that enrolled in this study could potentially hamper interpretation of the results if, differentially 
between cases and controls, carriers of certain alleles are over- or under-represented among 
those individuals who did not participate. It is reassuring, however, that the frequency of 
major HLA alleles among controls in our study is consistent with findings from other 
Caucasian populations.(28) For all subjects, it is not likely that a decision to participate in a 
research study is influenced by genetic factors. It is plausible, however, that certain HLA 
alleles could be over- or under-represented in our cases due to an impact on survival. If 
certain HLA alleles are associated with rapid progression of disease and poorer survival, 
these alleles may be under-represented in our case group, since 10.4% of SCC cases died 
prior to study enrollment. 
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This study is the first to report that commonly co-occurring class I and class II HLA 
alleles across loci may have a significant impact on cervical cancer development. They 
suggest that class II restricted CD4+ T helper as well as class I restricted CD8+ T effector cell 
recognition are necessary for a protective immune response to HPV-specific antigens or 
tumor antigens that may be unrelated to HPV. In this study, the presence of DQB1*0301 was 
found in most risk conferring allele combinations, and seemed to offset the reduced risk 
associated with DRB1*13 allele combinations if both DRB1*13 and DQB1*0301 were 
present.  
The similarities between results from our squamous cell cervical cancer, vulvar, and 
adenocarcinoma of the cervix studies support the view that the HLA associations reported in 
this study are likely HPV-specific. If these findings can be repeated in other studies with 
different populations, they warrant further investigation. The use of a prophylactic vaccine to 
stimulate immune response to initial HPV infections indicates that continued examination of 
immune response to HPV may lead to the development of novel therapies or effective 
vaccines against established HPV infections.  
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Table 1. Distribution of age, race, cigarette smoking, and 
lifetime number of sex partners among SCC cases and 
controls tested for HLA class I and II alleles 
 
Controls 
(N=542) 
 n % 
Cases 
(N=544) 
 n % 
Age     
18-29 76 (14.0) 60 (11.1)
30-39 175 (32.3) 180 (33.1)
40-49 151 (27.9) 151 (27.8)
50-59 68 (12.5) 83 (15.3)
60-69 43 (7.9) 56 (10.3)
70-74 29 (5.4) 14 (2.6)
Race     
White 513 (94.6) 481 (88.4)
Black 13 (2.4) 15 (2.8)
American Indian 0 (0.0) 6 (1.1)
Asian/Pacific Islander 10 (1.8) 25 (4.6)
Mixed 6 (1.1) 17 (3.1)
Smoking     
Never 262 (48.3) 203 (37.3)
Former 161 (29.7) 143 (26.3)
Current 119 (22.0) 198 (36.4)
Sex Partners     
1 131 (24.4) 54 (9.9)
2 to 4 149 (27.7) 168 (30.9)
5 to 14 195 (36.3) 229 (42.2)
15+ 62 (11.5) 92 (16.9)
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         Table 2. Risk of Squamous Cell Cervical Cancer Associated with HLA class I A, B, and Cw 
 alleles 
 Controls Cases     
 (N=504) (n=490)    Holm 
 n % n %  OR1 95% CI p-value2 
A*0101 154 (30.6) 143 (29.2) 1.0 (0.8-1.3)  
A*0201 249 (49.4) 213 (43.5) 0.8 (0.6-1.1)  
A*0301 120 (23.8) 143 (29.2) 1.4 (1.1-1.9) 0.02 
A*1101 60 (11.9) 59 (12.0) 1.0 (0.7-1.5)  
A*2402 76 (15.1) 90 (18.4) 1.2 (0.8-1.7)  
A*2902 40 (7.9) 27 (5.5) 0.7 (0.4-1.1)  
A*3201 31 (6.2) 40 (8.2) 1.5 (0.9-2.4)  
A*6801 28 (5.6) 25 (5.1) 0.9 (0.5-1.6)  
       
B*0702 127 (25.2) 140 (28.6) 1.2 (0.9-1.6)  
B*0801 124 (24.6) 89 (18.2) 0.7 (0.5-1.0) 0.15 
B*1501 57 (11.3) 31 (6.3) 0.6 (0.4-0.9) 0.02 
B*1801 38 (7.5) 29 (5.9) 0.8 (0.5-1.3)  
B*2705 43 (8.5) 28 (5.7) 0.7 (0.4-1.1)  
B*3501 54 (10.7) 46 (9.4) 0.8 (0.5-1.3)  
B*4001 58 (11.5) 61 (12.4) 1.1 (0.8-1.7)  
B*4402 70 (13.9) 112 (22.9) 1.9 (1.4-2.7) 0.0001 
B*4403 49 (9.7) 44 (9.0) 0.9 (0.6-1.4)  
B*5101 48 (9.5) 53 (10.8) 1.1 (0.7-1.7)  
B*5701 38 (7.5) 37 (7.6) 1.1 (0.7-1.7)  
       
Cw*0102 34 (6.7) 37 (7.6) 1.0 (0.6-1.7)  
Cw*0202 46 (9.1) 32 (6.5) 0.7 (0.4-1.2)  
Cw*0303 43 (8.5) 42 (8.6) 1.1 (0.7-1.7)  
Cw*0304 83 (16.5) 74 (15.1) 0.9 (0.7-1.3)  
Cw*0401 92 (18.3) 82 (16.7) 0.9 (0.6-1.2)  
Cw*0501 72 (14.3) 100 (20.4) 1.6 (1.2-2.3) 0.005 
Cw*0602 94 (18.7) 85 (17.3) 1.0 (0.7-1.3)  
Cw*0701 152 (30.2) 116 (23.7) 0.8 (0.6-1.0)  
Cw*0702 139 (27.6) 152 (31.0) 1.2 (0.9-1.5)  
Cw*0704 13 (2.6) 26 (5.3) 2.1 (1.0-4.1) 0.07 
Cw*0802 34 (6.7) 30 (6.1) 0.9 (0.6-1.5)  
Cw*1203 34 (6.7) 23 (4.7) 0.7 (0.4-1.2)  
Cw*1502 16 (3.2) 27 (5.5) 1.6 (0.8-3.0)  
Cw*1601 42 (8.3) 30 (6.1) 0.7 (0.4-1.1)  
                
1Odds ratios are adjusted for race. Bolding represents significant associations, although rounding 
sometime caused confidence intervals to include 1.0. 
2The Holm p value corrects the Wald p value for multiple comparisons and was based on all alleles at 
a locus and is only shown for alleles with significant odds ratios. 
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Table 3. Risk of Squamous Cell Cervical Cancer Associated with HLA class  
II DRB1 and DQB1 alleles 
 Controls Cases     
 (N=538) (n=538)    Holm 
 n % n    %  OR1 95% CI P value2 
DRB1*0101 79 (14.7) 80 (14.9)  1.1 (0.8-1.5)  
DRB1*0301 135 (25.3) 100 (18.6) 0.7 (0.5-1.0) 0.08 
DRB1*0401 100 (18.6) 121 (22.5) 1.4 (1.0-1.8) 0.22 
DRB1*0404 48 (8.9) 39 (7.2) 0.8 (0.5-1.3)  
DRB1*0701 139 (25.8) 132 (24.5) 1.0 (0.7-1.3)  
DRB1*0801 30 (5.6) 25 (4.6) 0.9 (0.5-1.5)  
DRB1*1101 33 (6.1) 65 (12.1) 2.1 (1.3-3.2) 0.001 
DRB1*1301 59 (11.0) 40 (7.4) 0.7 (0.4-1.0)   
DRB1*1302 49 (9.1) 28 (5.2) 0.5 (0.3-0.9) 0.03 
DRB1*1401 25 (4.6) 28 (5.2) 1.1 (0.6-1.9)  
DRB1*1501 143 (26.6) 147 (27.3) 1.1 (0.8-1.4)  
       
DQB1*02 225 (41.8) 183 (34.0) 0.7 (0.6-1.0) 0.04 
  DQB1*02013 135 (25.1) 100 (18.6) 0.7 (0.5-1.0) 0.08 
  DQB1*02023 101 (18.8) 87 (16.2) 0.9 (0.6-1.2)  
DQB1*0301 169 (31.4) 216 (40.1) 1.5 (1.1-1.9) 0.003 
DQB1*0302 119 (22.1) 111 (20.6) 0.9 (0.7-1.2)  
DQB1*0303 55 (10.2) 64 (11.9) 1.2 (0.8-1.7)  
DQB1*0402 23 (4.3) 28 (5.2) 1.1 (0.6-1.9)  
DQB1*0501 100 (18.6) 106 (19.7) 1.1 (0.8-1.5)  
DQB1*0503 23 (4.3) 28 (5.2) 1.2 (0.7-2.1)  
DQB1*0602 146 (27.1) 147 (27.3) 1.0 (0.8-1.4)  
DQB1*0603 61 (11.3) 43 (8.0) 0.7 (0.5-1.0)  
DQB1*0604 35 (6.5) 21 (3.9) 0.6 (0.3-1.0)  
                 
1Odds ratios are adjusted for race. Bolding represents significant associations, although rounding 
sometimes caused confidence intervals to include 1.0. 
2The Holm p value corrects the Wald p value for multiple comparisons and was based on all alleles at 
a locus and is only shown for alleles with significant odds ratios. 
3DQB1*02 could not be discerned as *0201 versus *0202 by the assay; see the Methods section. 
 26
 
Table 4. Significant risks of SCC associated with class I and II multilocus genotypes 
  Controls Cases   
  (N=502) (N=490)   
  Loci   Alleles n % n % OR1  95% CI 
A-B-Cw-DRB1-DQB1 0201-4402-0501-0401-0301 18 (3.6) 32 (6.5) 2.0 (1.1-3.7) 
    A-B-Cw-DRB1 0201-4402-0501-0401-xxxx 20 (4.0) 36 (7.4) 2.1 (1.2-3.6) 
    A-B-Cw-DQB1 0201-4402-0501-xxxx -0301 23 (4.6) 41 (8.4) 2.0 (1.2-3.3) 
    A-B-DRB1-DQB1 0201-4402-xxxx-0401-0301 20 (4.0) 34 (6.9) 1.9 (1.1-3.4) 
    B-Cw-DRB1-DQB1 xxxx -4402-0501-0401-0301 22 (4.4) 42 (8.6) 2.2 (1.3-3.7) 
       A-B-Cw 0201-4402-0501-xxxx-xxxx 43 (8.6) 59 (12.0) 1.5 (1.0-2.3) 
       A-B-DQB1 0201-4402-xxxx-xxxx-0301 27 (5.4) 50 (10.2) 2.1 (1.3-3.4) 
       A-B-DRB1 0201-4402-xxxx-0401-xxxx 22 (4.4) 38 (7.8) 2.0 (1.2-3.4) 
       A-Cw-DQB1 0201-xxxx -0501-xxxx-0301 23 (4.6) 44 (9.0) 2.1 (1.3-3.6) 
       A-Cw-DRB1 0201-xxxx-0501-0401-xxxx 20 (4.0) 37 (7.6) 2.1 (1.2-3.7) 
       A-DRB1-DQB1 0201-xxxx-xxxx-0401-0301 30 (6.0) 54 (11.0) 2.1 (1.3-3.3)* 
       B-Cw-DQB1 xxxx- 4402-0501-xxxx-0301 30 (6.0) 59 (12.0) 2.2 (1.4-3.6)* 
       B-Cw-DRB1 4402-0501-0401 25 (5.0) 49 (10.0) 2.3 (1.4-3.8)* 
       B-DRB1-DQB1 4402-0401-0301 24 (4.8) 45 (9.2) 2.1 (1.3-3.6) 
       Cw-DRB1-DQB1 0501-0401-0301 22 (4.4) 43 (8.8) 2.2 (1.3-3.8) 
            A-B 0201-4402 51 (10.2) 71 (14.5) 1.6 (1.1-2.3) 
            A-DQB1 0201-0301 74 (14.7) 108 (22.0) 1.7 (1.2-2.3)* 
            B-Cw 4402-0501 58 (11.6) 90 (18.4) 1.8 (1.3-2.6)* 
            B-DQB1 4402-0301 35 (7.0) 73 (14.9) 2.4 (1.6-3.7)* 
            B-DRB1 4402-0401 27 (5.4) 52 (10.6) 2.3 (1.4-3.7)* 
            Cw-DQB1 0501-0301 35 (7.0) 64 (13.1) 2.1 (1.4-3.2)* 
            Cw-DRB1 0501-0401 25 (5.0) 52 (10.6) 2.4 (1.5-4.0)* 
            DRB1-DQB1 0401-0301 55 (10.2) 81 (15.1) 1.7 (1.1-2.4) 
B-DRB1-DQB1 4402-1101-0301 3 (0.6) 28 (5.7) 10.0 (3.0-33.3*) 
        B-DRB1 4402-1101 3 (0.6) 29 (5.9) 10.5 (3.2-34.8)* 
        DRB1-DQB1 1101-0301 30 (5.6) 64 (11.9) 2.3 (1.4-3.6)* 
B-Cw-DQB1 0702-0702-0301 24 (4.8) 53 (10.8) 2.5 (1.5-4.2)* 
        B-DQB1 0702-0301 24 (4.8) 58 (11.8) 2.8 (1.7-4.5)* 
        Cw-DQB1 0702-0301 28 (5.6) 59 (12.0) 2.3 (1.4-3.7)* 
A-DQB1 0301-0501 28 (5.6) 42 (8.6) 1.7 (1.0-2.8) 
A-B 0201-1501 43 (8.6) 16 (3.3) 0.4 (0.2-0.7)* 
A-Cw 1101-0401 31 (6.2) 16 (3.3) 0.5 (0.3-1.0) 
A-DQB1 0201-0201 54 (10.8) 27 (5.5) 0.5 (0.3-0.8)* 
B-Cw 0801-0701 122 (24.3) 84 (17.1) 0.7 (0.5-0.9) 
Cw-DQB1 0701-02 110 (21.9) 76 (15.5) 0.7 (0.5-1.0) 
DRB1-DQB1 0301-02 136 (25.3) 100 (18.6) 0.7 (0.5-1.0) 
1Odds ratios are adjusted for race. Bolding represents significant associations, although 
rounding sometimes caused confidence intervals to include 1.0. 
*Holm test p-value < 0.05, result is significant after adjusting for multiple comparisons.  
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Table 5. Risk of SCC, adenocarcinoma of the cervix, and squamous cell vulvar cancer associated with selected class I and II multilocus genotypes 
 Controls SCC Cervix   Adenocarcinoma   Controls2 SCC Vulvar   
 (N=502) (n=490)   (n=537)   N=637) (n=424)   
 n (%) n (%) OR1 (95% CI) n (%) OR1 (95% CI) n (%) n (%) OR1 (95% CI) 
B*4402-DRB1*1101-DQB1*0301                
X-X-X 312 (62.0) 253 (52.0) ref  309 (57.5) ref  380 (59.7) 224 (52.8) ref  
4402-X-X 35 (7.0) 38 (7.8) 1.4 (0.9-2.3) 43 (8.0) 1.3 (0.8-2.0) 46 (7.2) 23 (5.4) 0.8 (0.5-1.4) 
X-1101-X 3 (0.6) 0 (0.0) --  1 (0.2) 0.3 (0.0-2.7) 5 (0.8) 1 (0.2) 0.4 (0.0-3.1) 
X-X-0301 92 (18.3) 91 (18.7) 1.2 (0.9-1.7) 100 (18.6) 1.1 (0.8-1.5) 112 (17.6) 56 (13.2) 0.8 (0.6-1.2) 
4402-1101-X 0 (0.0) 1 (0.2) --  0 (0.0)   0 (0.0) 0 (0.0)   
4402-X-0301 32 (6.4) 45 (9.2) 1.8 (1.1-3.0)* 37 (6.9) 1.2 (0.7-2.0) 47 (7.4) 40 (9.4) 1.4 (0.9-2.3) 
X-1101-0301 26 (5.2) 31 (6.4) 1.5 (0.8-2.5) 33 (6.1) 1.3 (0.8-2.2) 39 (6.1) 58 (13.7) 2.5 (1.6-3.9)* 
4402-1101-0301 3 (0.6) 28 (5.7) 11.5 (3.5-38.5)* 14 (2.6) 4.9 (1.4-17.2)* 8 (1.3) 22 (5.2) 4.7 (2.0-10.7)* 
                 
                 
B*0702-Cw*0702-DQB1*0301                
X-X-X 237 (47.1) 201 (41.0) ref  225 (41.9) ref  296 (46.5) 161 (38.0) ref  
0702-X-X 2 (0.4) 0 (0.0) --  2 (0.4) 1.1 (0.2-7.9) 3 (0.5) 3 (0.7) 1.8 (0.4-9.2) 
X-0702-X 10 (2.0) 11 (2.2) 0.9 (0.4-2.3) 11 (2.0) 1.1 (0.4-2.6) 15 (2.4) 4 (0.9) 0.5 (0.2-1.5) 
X-X-0301 125 (24.9) 132 (26.9) 1.3 (0.9-1.7) 140 (26.1) 1.2 (0.9-1.6) 167 (26.2) 126 (29.7) 1.4 (1.0-1.9) 
0702-0702-X 101 (20.1) 82 (16.7) 1.0 (0.7-1.4) 115 (21.4) 1.2 (0.9-1.7) 117 (18.4) 80 (18.9) 1.3 (0.9-1.8) 
0702-X-0301 0 (0.0) 5 (1.0) --  1 (0.2) --  1 (0.2) 0 (0.0) --  
X-0702-0301 4 (0.8) 6 (1.2) 1.2 (0.3-4.4) 6 (1.1) 1.3 (0.3-4.7) 5 (0.8) 0 (0.0) --  
0702-0702-0301 24 (4.8) 53 (10.8) 2.7 (1.6-4.6)* 37 (6.9) 1.7 (1.0-2.9) 33 (5.2) 50 (11.8) 2.8 (1.7-4.5)* 
                
B*0801-DRB1*0301-DQB1*0201                
X-X-X 346 (69.9) 379 (77.8) ref  396 (74.0) ref  450 (71.2) 321 (76.4) ref  
0801-X-X 25 (5.1) 15 (3.1) 0.6 (0.3-1.1) 21 (3.9) 0.7 (0.4-1.4) 30 (4.7) 23 (5.5) 1.1 (0.6-1.9) 
X-0301-X 0 (0.0) 0 (0.0) --  0 (0.0)   0 (0.0) 0 (0.0)   
X-X-0201 0 (0.0) 0 (0.0) --  0 (0.0)   0 (0.0) 0 (0.0)   
0801-0301-X 1 (0.2) 1 (0.2) 0.7 (0.0-11.3) 0 (0.0)   1 (0.2) 1 (0.2) 1.4 (0.1-22.2) 
0801-X-0201 0 (0.0) 0 (0.0) --  0 (0.0)   0 (0.0) 0 (0.0)   
X-0301-0201 29 (5.9) 16 (3.3) 0.5 (0.3-1.0) 26 (4.9) 0.8 (0.5-1.4) 36 (5.7) 23 (5.5) 0.9 (0.5-1.5) 
0801-0301-0201 97 (19.6) 73 (15.0) 0.7 (0.5-1.0) 92 (17.2) 0.8 (0.6-1.2) 115 (18.2) 52 (12.4) 0.6 (0.4-0.9) 
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Table 5, continued                 
DRB1*13-DQB1*06              
X-X 60 (10.1) 61 (16.1) ref  58 12.7 ref  70 (11.7) 54 (14.2) ref  
DRB1*13-X 2 (0.3) 0 (0.0)   0 0   3 (0.5) 0 (0.0)   
X-DQB1*06 77 (12.9) 71 (18.7) 0.9 (0.6-1.4) 77 16.8 1.1 (0.7-1.7) 84 (14.1) 73 (19.3) 1.1 (0.7-1.8) 
X-DQB1*0301 71 (11.9) 101 (26.6) 1.4 (0.9-2.2) 87 19 1.2 (0.8-2.0) 91 (15.2) 68 (17.9) 1.0 (0.6-1.5) 
X-DQB1*0302 56 (9.4) 50 (13.2) 0.9 (0.5-1.5) 52 11.4 1.0 (0.6-1.7) 65 (10.9) 46 (12.1) 0.9 (0.5-1.5) 
X-DQB1*0501 44 (7.4) 38 (10.0) 0.9 (0.5-1.5) 47 10.3 1.1 (0.6-1.9) 54 (9.0) 14 (3.7) 0.3 (0.2-0.7)* 
DRB1*13-DQB1*06 61 (10.2) 34 (9.0) 0.6 (0.3-1.0) 35 7.6 0.6 (0.3-1.0) 77 (12.9) 25 (6.6) 0.4 (0.2-0.7)* 
DRB1*13-DQB1*0301 7 (1.2) 9 (2.4) 1.4 (0.5-3.9) 2 0.4 0.3 (0.1-1.6) 7 (1.2) 7 (1.8) 1.3 (0.4-3.9) 
DRB1*13-DQB1*0302 1 (0.2) 1 (0.3) 0.7 (0.0-12.2) 0 0   1 (0.2) 0 (0.0)   
DRB1*13-DQB1*0501 0 (0.0) 0 (0.0)   1 0.2   0 (0.0)  (0.0)   
DRB1*13-DQB1*06/*0301 52 (8.7) 56 (14.8) 1.1 (0.6-1.8) 37 8.1 0.8 (0.4-1.3) 70 (11.7) 58 (15.3) 1.1 (0.6-1.7) 
DRB1*13-DQB1*06/*0302 30 (5.0) 29 (7.7) 1.0 (0.5-1.8) 37 8.1 1.3 (0.7-2.4) 42 (7.0) 23 (6.1) 0.7 (0.4-1.3) 
DRB1*13-DQB1*06/*0501 23 (3.9) 24 (6.3) 1.0 (0.5-2.1) 25 5.5 1.2 (0.6-2.3) 33 (5.5) 11 (2.9) 0.4 (0.2-0.9) 
1Odds ratios are adjusted for race. Bolding represents significant associations, although rounding sometimes caused confidence intervals to 
include 1.0. 
2Controls for the vulvar cancer study include women with a history of hysterectomy. 
*Holm test p-value < 0.05, result is significant after adjusting for multiple comparisons. 
 
